Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-05-03 | On April 15, 2016, we made the following option grants under the 2016 Plan. These grants will become void if the 2016 Plan is not approved by our stockholders: Garo Armen: 500,000 options at $1.25/share, vesting over 36 months |
| 2017-05-26 | Garo H. Armen, PhD, Executive Chairman, is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus Inc., a biotechnology company he co-founded in 1994. ... Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY. |
| 2018-06-13 | Garo H. Armen, PhD, Executive Chairman, is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus Inc., a biotechnology company he co-founded in 1994. ... Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year... Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York. |
| 2019-08-12 | Garo H. Armen, PhD, Executive Chairman, is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus Inc., a biotechnology company he co-founded in 1994. ... Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as years of expertise in the financial and biopharmaceutical arenas. ... The Nominating and Corporate Governance Committee consists of Joshua Silverman (Chair), Garo Armen, Ph.D., and Robert Stein, Ph.D. ... Summary Compensation Table shows Garo H. Armen, Chairman, 2017 total compensation $312,500. |
| 2020-08-28 | Garo H. Armen, Ph.D, Executive Chairman, is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus Inc., a biotechnology company he co-founded in 1994. ... Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as years of expertise in the financial and biopharmaceutical arenas. ... The Science Committee consists of Jennifer Buell, Ph.D. (Chair), Garo H. Armen, Ph.D. and Robert B. Stein, MD, Ph.D. ... Summary Compensation Table ... Garo H. Armen, Chairman ... 2017 ... Option Awards ($) ... 312,500 ... (1) We use the Black-Scholes option pricing model to value the options granted. On October 16, 2017, Dr. Armen was granted 250,000 options (exercise price of $1.75/option) under the 2016 Equity Compensation Plan which had 184,028 shares vested by December 31, 2019 valued at U.S. $1.25 each at December 31, 2019. |
| 2021-09-08 | Garo H. Armen, Ph.D, Executive Chairman, is one of our founders and joined us in September 2004. ... Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as years of expertise in the financial and biopharmaceutical arenas. ... The Audit Committee consists of Brian Corvese (Chairperson), Khalil Barrage, and Jennifer Bueull, PhD. The Board has designated Brian Corvese as an “audit committee financial expert,” as that term is defined by the NSADAQ Listing Rules and SEC regulations. ... The Science Committee consists of Jennifer Buell, Ph.D., Garo H. Armen, Ph.D. and Robert B. Stein, MD, Ph.D. (Chair). ... The Clinical and Regulatory Committee consists of Jennifer Buell, Ph.D. (Chair), Garo H. Armen, Ph.D. and Robert B. Stein, MD, Ph.D. ... Summary Compensation Table shows Garo H. Armen, Chairman, 2020 total compensation $411,185. |
| 2025-03-10 | Sincerely, /s/ Garo H. Armen Garo H. Armen Chairman |
Data sourced from SEC filings. Last updated: 2026-03-05